Meget 160

ndication:
MegetTM is indicated for the treatment of:
• Breast Cancer
• Endometrial Cancer

Dosage & Administration:
Breast Cancer: 160 mg/day taken once daily. At least two months of continuous treatment is considered an adequate period for determining the efficacy of Meget™.
Anorexia, cachexia or significant weight loss in patients with cancer: Usual adult dose: 400-800 mg as a single dose.
Children: Safety and effectiveness in pediatric patients have not been established. Meget™ is not recommended for use in children.
Elderly: In general, use in elderly patients should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.